Literature DB >> 27053209

Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.

Sarah Y Branch1, Cang Chen2, Ramaswamy Sharma3, James D Lechleiter3, Senlin Li4, Michael J Beckstead5.   

Abstract

Dopaminergic neurons of the substantia nigra (SN) play a vital role in everyday tasks, such as reward-related behavior and voluntary movement, and excessive loss of these neurons is a primary hallmark of Parkinson's disease (PD). Mitochondrial dysfunction has long been implicated in PD and many animal models induce parkinsonian features by disrupting mitochondrial function. MitoPark mice are a recently developed genetic model of PD that lacks the gene for mitochondrial transcription factor A specifically in dopaminergic neurons. This model mimics many distinct characteristics of PD including progressive and selective loss of SN dopamine neurons, motor deficits that are improved byl-DOPA, and development of inclusion bodies. Here, we used brain slice electrophysiology to construct a timeline of functional decline in SN dopaminergic neurons from MitoPark mice. Dopaminergic neurons from MitoPark mice exhibited decreased cell capacitance and increased input resistance that became more severe with age. Pacemaker firing regularity was disrupted in MitoPark mice and ion channel conductances associated with firing were decreased. Additionally, dopaminergic neurons from MitoPark mice showed a progressive decrease of endogenous dopamine levels, decreased dopamine release, and smaller D2 dopamine receptor-mediated outward currents. Interestingly, expression of ion channel subunits associated with impulse activity (Cav1.2, Cav1.3, HCN1, Nav1.2, and NavB3) was upregulated in older MitoPark mice. The results describe alterations in intrinsic and synaptic properties of dopaminergic neurons in MitoPark mice occurring at ages both before and concurrent with motor impairment. These findings may help inform future investigations into treatment targets for prodromal PD. SIGNIFICANCE STATEMENT: Parkinson's disease (PD) is the second most diagnosed neurodegenerative disorder, and the classic motor symptoms of the disease are attributed to selective loss of dopaminergic neurons of the substantia nigra. The MitoPark mouse is a genetic model of PD that mimics many of the key characteristics of the disease and enables the study of progressive neurodegeneration in parkinsonism. Here we have identified functional deficits in the ion channel physiology of dopaminergic neurons from MitoPark mice that both precede and are concurrent with the time course of behavioral symptomatology. Because PD is a progressive disease with a long asymptomatic phase, identification of early functional adaptations could lay the groundwork to test therapeutic interventions that halt or reverse disease progression.
Copyright © 2016 the authors 0270-6474/16/364026-12$15.00/0.

Entities:  

Keywords:  MitoPark; Parkinson's; dopamine; electrophysiology; mice; neurotransmission

Mesh:

Substances:

Year:  2016        PMID: 27053209      PMCID: PMC4821912          DOI: 10.1523/JNEUROSCI.1395-15.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  60 in total

1.  Impaired in vivo dopamine release in parkin knockout mice.

Authors:  Genko Oyama; Kenji Yoshimi; Shihoko Natori; Yoko Chikaoka; Yong-Ri Ren; Manabu Funayama; Yasushi Shimo; Ryosuke Takahashi; Taizo Nakazato; Shigeru Kitazawa; Nobutaka Hattori
Journal:  Brain Res       Date:  2010-07-08       Impact factor: 3.252

Review 2.  Genetic animal models of Parkinson's disease.

Authors:  Ted M Dawson; Han Seok Ko; Valina L Dawson
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

3.  IP3 receptor sensitization during in vivo amphetamine experience enhances NMDA receptor plasticity in dopamine neurons of the ventral tegmental area.

Authors:  Kee-Chan Ahn; Brian E Bernier; Mark T Harnett; Hitoshi Morikawa
Journal:  J Neurosci       Date:  2010-05-12       Impact factor: 6.167

4.  In vitro identification and electrophysiological characterization of dopamine neurons in the ventral tegmental area.

Authors:  Tao A Zhang; Andon N Placzek; John A Dani
Journal:  Neuropharmacology       Date:  2010-06-18       Impact factor: 5.250

5.  MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease.

Authors:  D Galter; K Pernold; T Yoshitake; E Lindqvist; B Hoffer; J Kehr; N-G Larsson; L Olson
Journal:  Genes Brain Behav       Date:  2009-10-07       Impact factor: 3.449

6.  The acid test of fluoride: how pH modulates toxicity.

Authors:  Ramaswamy Sharma; Masahiro Tsuchiya; Ziedonis Skobe; Bakhos A Tannous; John D Bartlett
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

7.  Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

Authors:  Xian Lin; Loukia Parisiadou; Xing-Long Gu; Lizhen Wang; Hoon Shim; Lixin Sun; Chengsong Xie; Cai-Xia Long; Wan-Jou Yang; Jinhui Ding; Zsu Zsu Chen; Paul E Gallant; Jung-Hwa Tao-Cheng; Gay Rudow; Juan C Troncoso; Zhihua Liu; Zheng Li; Huaibin Cai
Journal:  Neuron       Date:  2009-12-24       Impact factor: 17.173

Review 8.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

9.  Reliability in the identification of midbrain dopamine neurons.

Authors:  Elyssa B Margolis; Allison R Coker; Joseph R Driscoll; Anne-Iris Lemaître; Howard L Fields
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

10.  Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1.

Authors:  Jaime N Guzman; Javier Sanchez-Padilla; David Wokosin; Jyothisri Kondapalli; Ema Ilijic; Paul T Schumacker; D James Surmeier
Journal:  Nature       Date:  2010-11-10       Impact factor: 49.962

View more
  24 in total

1.  Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease.

Authors:  Souvarish Sarkar; Hai M Nguyen; Emir Malovic; Jie Luo; Monica Langley; Bharathi N Palanisamy; Neeraj Singh; Sireesha Manne; Matthew Neal; Michelle Gabrielle; Ahmed Abdalla; Poojya Anantharam; Dharmin Rokad; Nikhil Panicker; Vikrant Singh; Muhammet Ay; Adhithiya Charli; Dilshan Harischandra; Lee-Way Jin; Huajun Jin; Srikant Rangaraju; Vellareddy Anantharam; Heike Wulff; Anumantha G Kanthasamy
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

2.  Dopamine Deficiency Reduces Striatal Cholinergic Interneuron Function in Models of Parkinson's Disease.

Authors:  Jonathan W McKinley; Ziqing Shi; Ivana Kawikova; Matthew Hur; Ian J Bamford; Suma Priya Sudarsana Devi; Annie Vahedipour; Martin Darvas; Nigel S Bamford
Journal:  Neuron       Date:  2019-07-16       Impact factor: 17.173

3.  Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.

Authors:  Monica R Langley; Shivani Ghaisas; Muhammet Ay; Jie Luo; Bharathi N Palanisamy; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Neurotoxicology       Date:  2017-06-20       Impact factor: 4.294

4.  Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons.

Authors:  Alicia J Avelar; Jianjing Cao; Amy Hauck Newman; Michael J Beckstead
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

Review 5.  Heterogeneity of dopamine release sites in health and degeneration.

Authors:  Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2019-11-05       Impact factor: 5.996

6.  Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model.

Authors:  William B Lynch; Christopher W Tschumi; Amanda L Sharpe; Sarah Y Branch; Cang Chen; Guo Ge; Senlin Li; Michael J Beckstead
Journal:  Mov Disord       Date:  2018-11-15       Impact factor: 10.338

7.  Age-dependent alpha-synuclein accumulation is correlated with elevation of mitochondrial TRPC3 in the brains of monkeys and mice.

Authors:  Min Chen; Jia Liu; Yongquan Lu; Chunli Duan; Lingling Lu; Ge Gao; Piu Chan; Shun Yu; Hui Yang
Journal:  J Neural Transm (Vienna)       Date:  2016-11-30       Impact factor: 3.575

8.  Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.

Authors:  Muhammet Ay; Jie Luo; Monica Langley; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  J Neurochem       Date:  2017-05-09       Impact factor: 5.372

9.  Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator.

Authors:  Ji Won Choi; Su Jeong Shin; Hyeon Ji Kim; Jong-Hyun Park; Hyeon Jeong Kim; Elijah Hwejin Lee; Ae Nim Pae; Yong Sun Bahn; Ki Duk Park
Journal:  ACS Med Chem Lett       Date:  2019-06-03       Impact factor: 4.345

10.  Female mice are resilient to age-related decline of substantia nigra dopamine neuron firing parameters.

Authors:  Rebecca D Howell; Sergio Dominguez-Lopez; Sarah R Ocañas; Willard M Freeman; Michael J Beckstead
Journal:  Neurobiol Aging       Date:  2020-08-03       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.